The EGM authorised the board of directors to, in the period until the next annual general meeting, resolve on a new issue of shares with preferential rights for the company's shareholders. The total number of shares that may be issued based on the authorisation must be within the limits of the share capital according to the articles of association and may not exceed such number of shares corresponding to an issue proceeds of approximately SEK 100 million (before issue costs).

The purpose of the authorisation is to finance the company's growth-oriented business plan and to ensure continued successful development in accordance with the company's strategy where the proceeds from the rights issue is intended to be used to finance accelerated commercialization of Strangvac, regulatory processes for Strangvac in the US, Australia and New Zealand to obtain market approval, as well as further development of product candidates in the Company's project portfolio (INV274 and INV412).

For more information please contact:

Andreas Andersson, CEO

Phone: +46 (0)8 120 10601, Cell: +46 (0)73 335 99 70

E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on May 5, 2023, 13.40 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se,Phone: +46 (0)8 - 684 211 10